Request Appointment   MyChart Patient Portal   Interested in Research Studies-Patient Form New Patient Referrals-Physician Office Form Research Referrals-Physician Office Form
  • facebook.pngfacebook.png
  • twitter.pngtwitter.png
  • linkedin.pnglinkedin.png
Texas Liver Institute
  • Home
  • About
    • Research
    • Austin Office
    • Vision & Mission
    • Physicians and Advanced Practice Providers
    • Affiliations
    • Events
    • Disclosures
  • Services
    • Clinical Services
    • Nutrition Information
  • Education
    • About Your Liver
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C (HCV)
    • Chronic Hepatitis C
    • Autoimmune Hepatitis
    • Cirrhosis
    • Fatty Liver Disease
    • Liver Cancer
    • Hemochromatosis
    • Hepatocellular Carcinoma (HCC)
    • Primary Biliary Cholangitis (PBC)
    • Primary Sclerosing Cholangitis (PSC)
    • Health and Wellness
  • Conferences
    • 2022 Liver Conference Logistics
    • 2022 Liver Conference Slide Decks
    • 2022 Liver Conference Meeting Guide
  • Patient Resources
    • MyChart Patient Portal
    • What to Bring to Your Appointment
    • What to Expect During Your Visit
    • Working with Your Insurance
    • Our Financial Policies
    • Understanding Your Bill
    • Privacy Policy and HIPAA
    • FAQs
    • New Patient Forms
    • Paquete de Paciente Nuevo
  • Liver Updates
    • Liver News
    • Newsletters
    • Video Lectures
    • Slide Presentations
    • Most Recent Publications
  • Contact
    • Contact Us
    • Request Appointment!
    • New Patient Referrals-Physician Office Form

Nov 19 2021

Conversaciones con expertos del higado: Enfermedad del Higado Graso y sus progresiones

Sean Hendrickson

Media

Read More

Aug 20 2021

Dr. Rita Lepe and colleagues write: Uplifting the Latino Population From Obscurity to the Forefront of Health Care, Public Health Intervention, and Societal Presence

Sean Hendrickson

Media

The Latino population is the largest racial and ethnic minority group in the US. With approximately 60.6 million people, it comprises a bit more than 18% of the US population,

Read More

Aug 06 2021

KXXV: Woman shares her story of surviving hepatitis C to shatter stigma, encourage others to get tested

Sean Hendrickson

Media

“Well, I like to make jewelry,” said Ester LaRita. She is a talented jewelry maker who loves to spend time with her family. But her world changed overnight after one

Read More

Aug 06 2021

Listen to Dr. Poordad and Dr. Lawitz discuss rising Hepatitis C cases amid the pandemic on Texas Public Radio’s “The Source”

Sean Hendrickson

Media

SOURCE: https://www.tpr.org/podcast/the-source/2021-07-28/hepatitis-c-infections-are-on-the-rise-amid-the-pandemic-half-of-infected-people-dont-know-they-have-it

Read More

Jul 26 2021

Listen to Dr. Eugenia Tsai and other experts discuss the health risks of alcohol use/abuse on Texas Public Radio’s “The Source”

Sean Hendrickson

Media

SOURCE: https://www.tpr.org/podcast/the-source/2021-07-20/americans-are-drinking-more-to-cope-during-the-pandemic-what-are-the-health-risks

Read More

May 29 2021

Dr. Eric Lawitz Talks About Cirrhosis Awareness Key To Liver Health Improvement In NASH

Sean Hendrickson

Media

In an exclusive video with Healio Gastroenterology, Eric Lawitz, MD, from the Texas Liver Institute, The University of Texas Health, San Antonio, spoke about the NAVIGATE trial in nonalcoholic steatohepatitis-related

Read More

May 26 2021

¿Cómo detectar a tiempo la hepatitis C? Una experta explica sus vías de transmisión

Sean Hendrickson

Media

La doctora Rita Lepe nos explica cómo detectar a tiempo la hepatitis tipo C y qué tratamiento existe para esta enfermedad que provoca cirrosis del hígado, una condición que cobra

Read More

May 23 2021

Los latinos tienen 40% más probabilidad de morir por hepatitis C que la población blanca en EE.UU., según los CDC

Sean Hendrickson

Media

La hepatitis C es una enfermedad causada por un virus que afecta el hígado y puede ocasionar serios problemas de salud, como insuficiencia hepática, cirrosis, cáncer y hasta la muerte.

Read More

Feb 19 2021

People with Liver Diseases Suffer Higher COVID-19 Risk

Sean Hendrickson

Media

Written by Pramad Sukumaran | @pramod_ihpr Chronic liver disease can wreak havoc on the body, especially when there is a viral illness spreading worldwide. People suffering from Non-alcoholic Fatty Liver

Read More

Dec 16 2020

Hispanics and Liver Disease

Sean Hendrickson

Media

According to the 2019 US census, Hispanics make up 18.5% of the US population (60 million). In Texas, 39.7% of the population is Hispanic (11.5 million) and they primarily live

Read More

Oct 05 2020

hepatitis c, Dr. Phil, HCV

Dr. Poordad Discusses with Dr. Phil the Facts of Hepatitis C

Sean Hendrickson

Media

Read More

Oct 05 2020

Find the Missing Millions Video

Sean Hendrickson

Media

Read More

Oct 05 2020

Dr. Lawitz on The Dr. Joe Galati Podcast

Sean Hendrickson

Media

Listen to TLI’s Dr. Eric Lawitz discuss the latest advances in fatty liver disease on the Dr. Joe Galati podcast

Read More

Sep 21 2020

Dr. Fred Poordad is named 2020 Outstanding Medical Researcher

Sean Hendrickson

Media

Congratulations Dr. Fred Poordad for being named 2020 Outstanding Medical Researcher by the San Antonio Business Journal

Read More

Sep 21 2020

TLI’s Dallas Clinic Opening September 1, 2020

Sean Hendrickson

Media

Dr. Rita Lepe will be seeing patients at the new Dallas clinic 7515 Greenville AveSuite 600Dallas, Texas 75231 Phone : 214-945-2521Fax : 214-945-2524

Read More

May 01 2019

Hepatitis C Treatment Keeps Getting Better

Sean Hendrickson

Media

Bottom Line: With these therapies, only one in 1,000 hepatitis C patient will remain uncured. Sometimes progress seems to happen very slowly…and then all at once. Such is the case with treatments

Read More

Dec 05 2018

Do I have a fatty liver?

Sean Hendrickson

Media

A disease you may never have heard of is slowly damaging the health of a quarter of Americans. In San Antonio and the Valley, fatty liver disease affects nearly half

Read More

Nov 24 2018

Management of Nonalcoholic Fatty Liver Disease: Lessons Learned From Type 2 Diabetes

Sean Hendrickson

Media

By Naim Alkhouri, Fred Poordad, and Eric Lawitz Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of insulin resistance, which is the hallmark of type 2 diabetes (T2D). NAFLD

Read More

Feb 12 2018

Hepatitis C, Dr. Eric Lawitz, Texas Liver Institute

Looking Back on an Unprecedented Revolution in Medicine

Sean Hendrickson

Media

As we conclude another year now past the peak of hepatitis C research, HCV Nextasked me to consider where we came from, where we are now, and where we’re headed.

Read More

Dec 10 2017

HCV Patients SVR with Mavyret After Previous DAA Failure

Sean Hendrickson

Media

By Gail Connor Roche Patients with the hepatitis C virus (HCV) who received a 16-week regimen of glecaprevir and pibrentasvir (Mavyret) achieved high sustained virologic response (SVR) rates after previous treatments

Read More

Dec 10 2017

Childhood Obesity Epidemic

Sean Hendrickson

Media

BY LIZ HARROUN Due to rising rates of childhood obesity and diabetes in Texas, non-alcohol induced fatty liver disease is the number one need for transplant in young adults. We

Read More

Nov 16 2017

Dr. Eric Lawitz, of the Texas Liver Institute, Publishes on a New Standard of Care for Patients With Chronic Hepatitis C Infection and Severe Renal Impairment

Sean Hendrickson

Media

Dr. Eric Lawitz, internationally recognized for his work in liver disease, published groundbreaking results from a Phase 3 study in patients with chronic hepatitis C infection and severe renal impairment.   The

Read More

Oct 24 2017

Fatty liver disease fastest-growing reason for transplants in young U.S. adults

Sean Hendrickson

Media

(Reuters Health) – Nonalcoholic fatty liver disease and its more aggressive form, nonalcoholic steatohepatitis, have become the fastest-growing reasons for liver transplants in young Americans, according to a recent study.

Read More

Sep 25 2017

Mavyret safe, effective for HCV genotype 3 regardless of cirrhosis

Sean Hendrickson

Media

Patients with hepatitis C genotype 3, with or without compensated cirrhosis, achieved significantly high rates of sustained virologic response after treatment with Mavyret and experienced no significant adverse events related

Read More

Aug 24 2017

Cirrhosis, Now Linked to NAFLD, Presents Management Challenges

Sean Hendrickson

Media

Cirrhosis, or advanced fibrosis of the liver, presents with many challenges such as complications associated with portal hypertension, but in today’s medical climate, it must also be considered in relation

Read More

Aug 21 2017

Does Liver Disease Hurt? Ask a Hepatologist!

Sean Hendrickson

Media

Does liver disease hurt? This is a common question that our hepatologists are asked at the Texas Liver Institute so we decided to answer it! The liver does not contain

Read More

Aug 17 2017

Is acetaminophen (Tylenol®) or NSAIDS (ibuprofen or asprin) safe for individuals with liver disease?

Sean Hendrickson

Media

Is acetaminophen (Tylenol®) or NSAIDS (ibuprofen or asprin) safe for individuals with liver disease? Contrary to many peoples beliefs, acetaminophen can be used in patients with chronic liver disease (CLD). 

Read More

Aug 08 2017

HCV Drug

PANGENOTYPIC HCV REGIMENS: ALL FOR ONE AND ONE FOR ALL

Sean Hendrickson

Media

PANGENOTYPIC HCV REGIMENS: ALL FOR ONE AND ONE FOR ALL It’s no secret the incredible advancements in Hepatitis C treatment over the past 5 years, but it may come as a surprise

Read More

Aug 04 2017

fibroscan, ultrasound elastography, fatty liver disease

Transient Elastography (FibroScan)

Sean Hendrickson

Media

Transient Elastography (FibroScan) Non-Invasive Liver Fibrosis Assessment Accurately staging liver disease is important in the determination for and monitoring of a treatment regimen. A well-studied technology has become available to

Read More

Jul 31 2017

Protect yourself from liver disease

Sean Hendrickson

Media

Liver disease is serious and can go undetected for years. That is why the Texas Liver Institute offers seminars, free screens and lots more. Watch this video to learn more

Read More

Apr 27 2017

Next Generation HCV Therapy Presented at the International Liver Congress™ 2017 by Texas Liver Institute’s Dr. Fred Poordad | Company Newsroom of Texas Liver Institute

Sean Hendrickson

Media

Study findings shed light on effective new HCV therapy that will treat patients who have failed other therapies San Antonio, Texas, April 27, 2017 (Newswire.com) – Dr. Fred Poordad, internationally

Read More

Apr 04 2017

Texas Liver Institute Welcomes Dr. Naim Alkhouri as Director of the Metabolic Center

Sean Hendrickson

Media

SAN ANTONIO, /PRNewswire/ — The Texas Liver Institute announced that Dr. Naim Alkhouri has joined the staff as their Director of the Metabolic Center and will have a leadership role in

Read More

Feb 23 2017

An alarming trend in fatty livers | The Lancet USA Blog

Sean Hendrickson

Media

By Ray Cavanaugh Ray Cavanaugh is a freelance writer from Boston, MA. His interests include history, health topics, and current events in faraway places. They have fatty liver disease, but

Read More

Oct 29 2016

KEN5 – Real Men Wear Gowns: Fatty Liver Disease

Sean Hendrickson

Media

Fatty liver is a condition where the liver becomes infiltrated with fat. Most people with fatty liver are overweight, have diabetes or pre-diabetes.

Read More

Oct 13 2016

Real Men Wear Gowns: Treating Fatty Liver Disease | kens5.com

Sean Hendrickson

Media

SAN ANTONIO — Fatty liver disease can be caused by drinking too much, but in many men genetics and diet can trigger the illness. “There are a lot of untapped

Read More

Jun 10 2016

Survival rates rise with new hepatitis C treatments – San Antonio Business Journal

Sean Hendrickson

Media

Just a few years ago the outlook for treating patients with chronic hepatitis C was grim. For almost a year, patients would receive a complicated regimen of shots and up

Read More

May 05 2016

Dr. Fred Poordad talks hepatitis C with Dr. Phil

Sean Hendrickson

Media

Watch the Dr. Phil interview with Dr. Poordad

Read More

Apr 17 2016

MAGELLAN-I: Novel regimen yields strong results in experienced patients with RAVs

Sean Hendrickson

Media

BARCELONA —  Combination therapy with ABT-493, a novel NS3/4A protease inhibitor, and ABT-530, a pangenotypic NS5A inhibitor, produced sustained virologic response rates around 90% in a cohort of treatment-experienced patients,

Read More

Apr 16 2016

Combo Tx Offers ‘Salvage’ in Tough-to-Treat HCV | Medpage Today

Sean Hendrickson

Media

BARCELONA — An investigational drug combination offers renewed hope of a cure for chronic hepatitis C (HCV) patients who have tried and failed therapy with the new direct-acting antiviral agents,

Read More

Apr 15 2016

‘Triple therapy’ shows efficacy in treatment-experienced patients

Sean Hendrickson

Media

BARCELONA — A new three-pronged approach to hepatitis C virus effectively treated prior non-responders with genotype 1, according to a presenter at the International Liver Congress. “As increasing numbers of

Read More

Apr 15 2016

New pan-genotypic combination effectively treats DAA failures

Sean Hendrickson

Media

BARCELONA — In this video perspective from the International Liver Congress, Fred Poordad, MD, discusses the combination treatment of ABT-493 and ABT-530 (AbbVie) for patients who previously failed direct-acting antiviral

Read More

Apr 15 2016

AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals

Sean Hendrickson

Media

– 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with and without RBV in GT1 chronic HCV infected patients without cirrhosis who failed previous therapy

Read More

Apr 15 2016

AbbVie (ABBV) Issues Positive Update on ABT-493 and ABT-530 w/ RBV in HCV GT1 (ENTA)

Sean Hendrickson

Media

AbbVie (NYSE: ABBV) announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with

Read More

May 27 2015

DAAS in the Pipeline: What‘s coming?

Sean Hendrickson

Media

http://medpagetoday.s3.amazonaws.com/media/sponsors/hothcv/Pipeline2.mp4 MedPage Today invited specialists from leading medical institutions to weigh in on the latest advancements in hepatitis C with one question each day for 10 days. In this installment,

Read More

May 20 2015

FDA expedites development of hepatitis C drugs

Sean Hendrickson

Media

The U.S. Food and Drug Administration has granted amended Breakthrough Therapy Designation for an investigational combination of drugs that show great promise for treating the sickest hepatitis C patients—those with

Read More

May 18 2015

Who is at risk and how can they be reached?

Sean Hendrickson

Media

MedPage Today invited specialists from leading medical institutions to weigh in on the latest advancements in hepatitis C with one question each day for 10 days. In this installment, we

Read More

May 12 2015

S.A. Hep C patients free of disease following new treatment

Sean Hendrickson

Media

At the time, the medication Joey was taking kept the disease from progressing. But it had debilitating side effects. “I would feel the side effects like days after. It would

Read More

May 07 2015

Treatment Curing Patients with Advanced Hepatitis C Symptoms – KABB – San Antonio Top Stories – News, Sports, Weather, Traffic

Sean Hendrickson

Media

A medical breakthrough tested in San Antonio is opening doors for patients diagnosed with hepatitis C. The virus can be deadly, but now researchers say they’ve found a cure for

Read More

May 05 2015

UNITY-1: Fixed-dose combo yields high SVR12 in HCV patients without cirrhosis

Sean Hendrickson

Media

Treatment-naive and experienced patients with chronic hepatitis C virus genotype 1 infection without cirrhosis achieved a sustained virologic response at 12 weeks while on a fixed-dose regimen of daclatasvir, asunaprevir

Read More

May 05 2015

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B) | BMS Newsroom

Sean Hendrickson

Media

97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients with HCV genotype 3 achieved cure   No need seen to alter existing transplantation medication regimens

Read More

May 05 2015

Merck releases phase III data of grazoprevir/elbasvir to treat chronic hepatitis C virus – Pharmaceutical Business Review

Sean Hendrickson

Media

Merck has released first presentations of data from C-EDGE phase III clinical trial of grazoprevir/elbasvir in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV)

Read More

May 05 2015

Janssen announces results for its HCV treatment simeprevir

Sean Hendrickson

Media

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced results for its hepatitis C treatment simeprevir at The International Liver Congress™ 2015. New

Read More

May 05 2015

Could Merck & Co., Inc.’s (MRK) Hepatitis C Drugs Be A Threat To Gilead Sciences, Inc. (GILD) And AbbVie Inc (ABBV)?

Sean Hendrickson

Media

Bidness Etc takes a look at how Merck’s new drug is different from the currently available drugs by Gilead and AbbVie and what analysts think about the competition it can

Read More

May 05 2015

HIV & AIDS Information :: When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration

Sean Hendrickson

Media

More than 70% of people with chronic genotype 1 hepatitis C who did not achieve a sustained virological response when treated with sofosbuvir/ledipasvir (Harvoni) for 8 or 12 weeks were

Read More

May 05 2015

HIV & AIDS Information :: Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants

Sean Hendrickson

Media

An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced liver cirrhosis and

Read More

May 05 2015

HCV Drug Combo Succeeds in Advanced Disease | Medpage Today

Sean Hendrickson

Media

VIENNA — An investigational drug combination had high efficacy among patients with cirrhosis associated with hepatitis C (HCV) or recurrence of the disease after a transplant, researchers said here. But

Read More

May 05 2015

Need for Speed Defines Hepatitis C Race for Gilead, Achillion – Bloomberg Business

Sean Hendrickson

Media

With Merck & Co. poised to disrupt competitors with new hepatitis C drugs, rivals are scrambling to get ahead the best way they can figure: make a medicine that works

Read More

May 05 2015

ALLY-1 Results: More Good News on Hep C

Sean Hendrickson

Media

Results of trials of antivirals to treat hepatitis C infections are dominating the proceedings at the 2015 International Liver Congress in Vienna, Austria. In a presentation today, Fred Poordad, MD,

Read More

May 05 2015

Hepatitis C: Interferon’s Return Stirs Controversy

Sean Hendrickson

Media

The use of interferon to treat hepatitis C infections has fallen out of favor with the advent of new antivirals and drug combinations that have fewer side effects. But in

Read More

May 05 2015

C-SWIFT: 8 weeks of therapy may be possible with grazoprevir/elbasvir

Sean Hendrickson

Media

VIENNA — Patients with cirrhosis as well as genotype 1 and genotype 3 HCV responded favorably to 8 weeks of treatment with a novel grazoprevir and elbasvir-based combination regimen, according

Read More

May 05 2015

Previous treatment failures respond to 24 weeks of Harvoni

Sean Hendrickson

Media

VIENNA — Twenty-four weeks of treatment with Harvoni yielded a 12-week sustained virologic response rate higher than 70% in a cohort of patients who had failed previous therapies, according to

Read More

May 05 2015

HSC NEWS – Study shows promising results for curing hard-to-treat hepatitis C in patients awaiting or completing liver transplant

Sean Hendrickson

Media

UT Health Science Center San Antonio doctor presents results of daclatasvir regimen SAN ANTONIO (April 30 2015) — A number of new, highly effective oral treatments for various types of

Read More

May 01 2015

Merck says experimental Hepatitis C treatment shows 95% cure rate – MarketWatch

Sean Hendrickson

Media

Merck & Co. said Friday that its experimental drug combination for treating chronic hepatitis C patients demonstrated a 95% effective rate in a late-stage study. The study combined grazoprevir and

Read More

May 01 2015

Study results promising for hepatitis C patients awaiting or completing liver transplant

Sean Hendrickson

Media

A number of new, highly effective oral treatments for various types of hepatitis C have been approved in the past few years. However, two groups who have not benefitted from

Read More

Feb 01 2015

Gastroenterology & Endoscopy News – Shorter Hepatitis C Treatment Durations May Be a Reality

Sean Hendrickson

Media

Boston—Can treatment of hepatitis C infection with new direct-acting antivirals (DAAs) be shortened to less than 12 weeks? Interim results from a recent trial suggest treatment durations of eight or

Read More

Jan 10 2015

Advances in Chronic Hepatitis C Management and Treatment

Sean Hendrickson

Media

Following this program, participants should be better able to: Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at AASLD 2014 Employ current treatment protocols

Read More

Dec 31 2014

Beclabuvir with PEG-IFN a-2a/ribavirin safely treated HCV

Sean Hendrickson

Media

In a phase 2a clinical trial, treatment with beclabuvir and a combination of pegylated interferon alfa-2a and ribavirin was well tolerated among patients with hepatitis C virus genotype 1 infection,

Read More

Dec 19 2014

FDA Approves AbbVie’s Hepatitis Treatment

Sean Hendrickson

Media

Multidrug Regimen Seen Challenging Recently Approved Drugs from Gilead Sciences U.S. regulators on Friday approved AbbVie Inc.’s new multidrug regimen for hepatitis C, the latest in a wave of new

Read More

Dec 19 2014

AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C

Sean Hendrickson

Media

– In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure – Tolerability profile shows more

Read More

Nov 21 2014

Obesity can lead to liver disease

Sean Hendrickson

Media

It’s becoming health threat at young age When David Martinez was diagnosed with advanced cirrhosis of the liver, he was surprised and confused. “I thought cirrhosis came from drinking,” said

Read More

Nov 16 2014

Investigational HCV Combo Delivers in Differing Groups

Sean Hendrickson

Media

Two studies suggest drugs could yield high cure rates. A new study suggests that some subgroups of patients with hepatitis C (HCV) infection can achieve sustained virologic responses (SVR) in

Read More

Nov 13 2014

Shorter Treatment Shows Promise With Investigative HCV Agents

Sean Hendrickson

Media

Can outcomes be sustained with shorter regimens? A new study suggests that some subgroups of patients with hepatitis C virus infectioncan achieve sustained virologic responses (SVR) in as short as

Read More

Nov 12 2014

Liver cancer reaches epidemic levels in South Texas

Sean Hendrickson

Media

S. Texas Latinos have nation’s highest rate Experts are sounding the alarm on liver cancer, which has reached epidemic levels in South Texas, likely because of the region’s high rates

Read More

Nov 09 2014

General Hepatology Update – The Liver Meeting® 2014

Sean Hendrickson

Media

We got an overview on this important session at The Liver Meeting® 2014 which aims to investigate the latest on clinical issues commonly seen in practice. Diagnostic strategies and approaches

Read More

Jul 29 2014

Local Doctor Finds Cure for Hepatitis C

Sean Hendrickson

Media

A San Antonio doctor has published a cure for hepatitis C, one of the most painful, and expensive, diseases in the world, News Radio 1200 WOAI reports. Dr. Eric Lawitz,

Read More

Jul 28 2014

New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients

Fred Poordad

Media

San Antonio researcher leads national study that included hard-to-treat patients SAN ANTONIO ― Researchers from The University of Texas Health Science Center at San Antonio, the Texas Liver Institute and

Read More

May 30 2014

All Oral Therapy for Hepatitis C Cures Most Patients Infected with Hepatitis C after Liver Transplant

Sean Hendrickson

Media

Miami, Florida — New data offers hope to liver transplant patients infected with the hepatitis C virus.  This virus may lead to liver destruction and cancer in up to 40% of the

Read More

Apr 22 2014

Three-drug Regimen Offers Positive Outcomes For Genotype 1 HCV Cirrhotic Patients, According To Texas-Based Researchers

Sean Hendrickson

Media

A new study published in the New England Journal of Medicine and presented at the International Liver Congress highlights the use of a multitargeted therapy that combines the drug ABT-450 with

Read More

Apr 17 2014

Cure For Hepatitis C Could Eradicate Disease In 15 Years

Sean Hendrickson

Media

A San Antonio researcher has announced that he has found a cure for Hepatitis C. In the first-of-its-kind study dedicated to patients with Hepatitis C and cirrhosis of the liver,

Read More

Apr 16 2014

TURQUOISE-II: Three-drug regimen yields high SVR in genotype 1 cirrhotic patients

Sean Hendrickson

Media

Multitargeted therapy of ABT-450 with ritonavir, ombitasvir and dasabuvir yielded strong response rates with few discontinuations among patients with cirrhosis and hepatitis C genotype 1 treated for 12 or 24

Read More

Apr 14 2014

3D Combo Works in Cirrhotic HCV Patients, Too

Sean Hendrickson

Media

A drug combination with striking efficacy in relatively healthy hepatitis C (HCV) patients had similar outcomes in patients with compensated cirrhosis, a researcher said. In an open-label phase III trial,

Read More

Apr 14 2014

UT Medicine San Antonio & Texas Liver Institute Researchers Cure 90% of Studied Hepatitis C Patients

Sean Hendrickson

Media

An international study including researchers from University of Texas Medicine San Antonio and Texas Liver Institute announced significant success in the treatment of hepatitis C infection in patients with liver cirrhosis.

Read More

Apr 12 2014

Hepatitis C treatment cures over 90 percent of patients with cirrhosis

Fred Poordad

Media

Oral combination proves safe for patients who could not have interferon therapy SAN ANTONIO, Texas — A novel 12 week regimen of pills has cured more than 90% of hepatitis

Read More

Nov 05 2013

Drug Combo Cures 97 Percent of Hep C Patients in Study

Sean Hendrickson

Media

An experimental trial of two drugs in one pill had a high cure rate for patients infected with hepatitis C. A new drug combination has effectively cured hepatitis C in

Read More

Patient Education

  • About Your Liver
  • Hepatitis
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C (HCV)
    • Chronic Hepatitis C
    • Autoimmune Hepatitis
  • Fatty Liver Disease
  • Liver Cancer
  • Cirrhosis
  • Hemochromatosis
  • PBC/PSC

Appointments

  • Schedule an Appointment!
  • What to Bring to Your Appointment
  • What to Expect During Your Visit
  • Working with Your Insurance
  • Our Financial Policies
  • Privacy Policy and HIPAA
  • FAQs
  • Patient Forms

Locations

San Antonio-Central

607 Camden St
Suite 101
San Antonio, Texas 78215

Phone : 210-253-3426

Fax : 210-227-6951

San Antonio-Medical Center

4751 Hamilton Wolfe Road
Suite 200
San Antonio, TX 78229

Phone : 210-253-3426

Fax : 210-227-6951

Austin

7940 Shoal Creek Blvd
Suite 205
Austin, Texas 78757

Phone : 512-454-8378

Fax : 512-454-8375

Disclosures

Copyright © 2022 Texas Liver Institute, All Rights Reserved
Texas Liver Institute